Want to see GB:GENF full AI Analyst Report?
Top Page
Genflow Biosciences Plc
(LSE:GENF)
Select Model
Select Model
Rating:42Neutral
Price Target:
1.50 p
▼(-26.83% Downside)
Action:Reiterated
Date:10/14/26
The score is weighed down primarily by weak financial performance (declining revenue, heavy losses, and ongoing cash burn), with technicals also negative (trading below all major moving averages and negative MACD). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Debt-Free Balance Sheet
The absence of debt reduces interest obligations and refinancing exposure, giving the company more flexibility than a similarly loss-making biotech with leverage. This supports continued investment in research while limiting the direct financial burden during development.
Negative Factors
Declining Revenue
Declining revenue indicates weakening commercial traction and reduces the resources available to fund research internally. For an early-stage biotechnology company, sustained top-line contraction can delay development progress and increase dependence on future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of debt reduces interest obligations and refinancing exposure, giving the company more flexibility than a similarly loss-making biotech with leverage. This supports continued investment in research while limiting the direct financial burden during development.
Read all positive factors
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£10.85M
Dividend YieldN/A
Average Volume (3M)3.15M
Price to Earnings (P/E)―
Beta (1Y)-0.18
Revenue GrowthN/A
EPS Growth56.00%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding594,534,800
10 Day Avg. Volume957,006
30 Day Avg. Volume3,146,086
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genflow Biosciences Plc Business Overview & Revenue Model
Company Description
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology compan...
Genflow Biosciences Plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 585.61K | 0.00 | 0.00 | 169.85K | 0.00 | 0.00 |
| Gross Profit | 585.61K | -1.09K | -1.20K | -1.03K | -130.00 | 0.00 |
| EBITDA | -1.10M | -2.00M | -1.59M | -1.80M | -1.33M | -988.10K |
| Net Income | -1.10M | -1.42M | -1.59M | -1.63M | -1.34M | -988.29K |
Balance Sheet | ||||||
| Total Assets | 748.99K | 452.39K | 385.91K | 1.07M | 2.62M | 276.55K |
| Cash, Cash Equivalents and Short-Term Investments | 632.55K | 111.79K | 278.68K | 683.97K | 2.36M | 224.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 559.14K | 1.00M | 788.92K | 345.74K | 250.99K | 221.43K |
| Stockholders Equity | 189.85K | -550.78K | -403.01K | 725.91K | 2.37M | 55.12K |
Cash Flow | ||||||
| Free Cash Flow | -1.23M | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Operating Cash Flow | -1.23M | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Investing Cash Flow | -652.00 | 0.00 | 0.00 | -2.44K | -2.48K | 198.50K |
| Financing Cash Flow | 1.59M | 1.31M | 656.63K | 0.00 | 3.50M | 783.71K |
Genflow Biosciences Plc Technical Analysis
Neutral
2.05
Price Trends
1.97
Negative
1.98
Negative
2.03
Negative
Market Momentum
-0.05
Negative
46.41
Neutral
67.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENF, the sentiment is Neutral. The current price of 2.05 is above the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.97, and above the 200-day MA of 2.03, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 46.41 is Neutral, neither overbought nor oversold. The STOCH value of 67.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:GENF.
Genflow Biosciences Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £82.07M | -4.57 | -316.73% | ― | -56.10% | -16.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | £6.88M | -5.56 | -97.87% | ― | 7.38% | 44.13% | |
43 Neutral | £10.92M | -10.50 | -46.61% | ― | 28.35% | 57.14% | |
42 Neutral | £10.85M | -8.30 | 609.63% | ― | ― | 56.00% | |
42 Neutral | £2.15M | -2.38 | -152.03% | ― | 20.05% | -11.11% | |
40 Underperform | £15.79M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:GENF
Genflow Biosciences Plc
1.90
-0.20
-9.52%
GB:OBD
Oxford BioDynamics
0.11
-0.21
-65.63%
GB:PYC
Physiomics
0.48
<0.01
2.15%
GB:FAB
Fusion Antibodies Plc
6.25
-6.50
-50.98%
GB:4BB
4basebio UK Societas
530.00
-255.00
-32.48%
GB:APTA
Aptamer Group Plc
0.30
-0.55
-64.71%
Genflow Biosciences Plc Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Genflow strengthens SIRT6 patent in Japan and broadens animal health pipeline
Positive
Oct 9, 2026
Genflow Biosciences has secured a decision to grant from the Japan Patent Office for a patent covering SIRT6 variants used to prevent and treat age-related diseases, reinforcing protection for the core gene therapy platform in one of the worldR...
Business Operations and StrategyProduct-Related Announcements
Genflow’s SIRT6c Gene Therapy Shows Promising Interim Results in Ageing Dog Trial
Positive
Oct 5, 2026
Genflow Biosciences reported interim results from its SLAB-VET-001 canine trial, a four-arm blinded study in 24 aged Beagles testing its centenarian-derived SIRT6c gene therapy delivered via plasmid DNA or AAV8 versus saline. The therapy was gener...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Genflow Biosciences boosts capital with warrant exercise and new share issuance
Positive
Sep 29, 2026
Genflow Biosciences Plc has strengthened its capital base through the exercise of warrants resulting in the issue of 28,124,999 new ordinary shares, generating gross proceeds of £309,375 for the company. The new shares, issued at an adjusted ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Genflow Biosciences Hits Canine Longevity Milestone and Expands Human Aging Pipeline
Positive
Sep 29, 2026
Genflow Biosciences reported half-year results marked by the successful completion of its SLAB clinical trial in aged Beagle dogs, confirming safety and tolerability of its GF-1004 SIRT6-based therapy and generating functional healthspan data. Thi...
Business Operations and Strategy
Genflow hits key ageing marker in dog gene‑therapy trial, eyes animal health deals
Positive
Sep 8, 2026
Genflow Biosciences has completed its SLAB clinical trial in aged beagles, testing a proprietary SIRT6 centenarian gene therapy delivered via naked DNA and AAV8, and achieved the primary endpoint of reducing biological age as measured by the GRIM ...
Business Operations and StrategyExecutive/Board Changes
Genflow Biosciences hires ON365 to bolster investor outreach as SIRT6 gene therapy advances
Positive
Sep 7, 2026
Genflow Biosciences Plc, an emerging player in longevity research developing SIRT6-based gene therapies for age-related conditions, is advancing its lead candidate GF-1002 through preclinical and early clinical programmes. The company aims to addr...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Genflow Advances SIRT6 Patent Portfolio to Bolster Longevity Gene Therapy Strategy
Positive
Aug 3, 2026
Genflow Biosciences, a UK-based biotechnology firm specializing in gene therapies for age-related diseases and longevity, is advancing its lead SIRT6-based candidate GF-1002 through preclinical and clinical programs. The company aims to address si...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.